Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl]allyl- N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK1/NK2 receptor antagonist

Journal of Medicinal Chemistry

Volumn 46, Issue 16, 2003, Pages 3508-3513

  Gerspacher, Marc ^a   Lewis, Christine ^b   Ball, Howard A ^a   Howes, Colin ^b   Subramanian, Natarajan ^a   Ryffel, Karin ^a   Fozard, John R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; DNK 333; N [1 (3,4 DICHLOROBENZYL) 3 (2 OXOAZEPAN 3 YL)CARBAMOYL]ALLYL N METHYL 3,5 BIS(TRIFLUOROMETHYL)BENZAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRONCHOSPASM; DIASTEREOISOMER; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; GUINEA PIG; HUMAN; IN VIVO STUDY; MOLECULAR CLONING; NONHUMAN; RECEPTOR AFFINITY; SQUIRREL MONKEY; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ANIMALS; AZA COMPOUNDS; BENZAMIDES; BIOLOGICAL AVAILABILITY; BRONCHOCONSTRICTION; CHO CELLS; CRICETINAE; GUINEA PIGS; HUMANS; MALE; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SAIMIRI; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0041842669     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030786m     Document Type: Article

References (32)

1. (a) Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 1993, 13, 23-93.
2. (b) Regoli, D.; Boudon, A., Fauchére, J.-L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 1994, 46 (4), 551-599.
3. (c) Maggio, J. E.; Mantyh, P. W. History of Tachykinin Peptides. In The Tachykinin Receptors; Buck, S. H., Eds.; Humana: Totowa, NJ, 1994; pp 1-21.
4. Nakanishi, S. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 1994, 14, 123-136.
5. Bellucci, F.; Carini, F.; Catalani, C.; Cucchi, P.; Lecci, A.; Meini, S.; Patacchini, R.; Quartara, L.; Ricci, R.; Tramontana, M.; Giuliani, S.; Maggi, C. A. Pharmacological profile of the novel mammalian tachykinin hemokinin 1. Br. J. Pharmacol. 2002, 135, 266-274.
6. (a) Burcher, E.; Mussap, C. J.; Stephenson, J. A. Autoradiographic localization of receptors in peripheral tissues. In The Tachykinin Receptors; Buck, S. H., Eds.; Humana: Totowa, NJ, 1994; pp 125-163.
7. (b) Krause, J. E.; Blount, P.; Sachais, B. S. Molecular Biology of Receptors. In The Tachykinin Receptors; Buck, S. H., Eds.; Humana: Totowa, NJ, 1994, pp 165-218.
8. (a) Longmore, J.; Swain, C. J.; Hill, R. G. Neurokinin receptors. Drug News Perspect. 1995, 8 (1), 5-23.
9. (b) Kucharczyk, N. Tachykinin antagonists in development. Expert Opin. Invest. Drugs 1995, 4 (4), 299-311.
10. (c) Elliott, J.; Seward, E. M. Neurokinin receptor antagonists. Expert Opin. Ther. Pat. 1997, 7 (1), 43-54.
11. (d) Longmore, J.; Hill, R. G.; Hargreaves, R. J. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmacol. 1997, 75, 612-621.
12. (e) von Sprecher, A.; Gerspacher, M.; Anderson, G. P. Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis. Drugs 1998, 1 (1), 73-91.
13. 2 receptor antagonists. Drugs Future 1999, 24 (8), 883-892.
14. (b) Kudlacz, E. M.; Scott, A.; Shatzer, S. A.; et al. In vitro and in vivo characterisation of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonists. J. Pharmacol. Exp. Ther. 1996, 277, 840-851.
15. (c) Rumsey, W. L.; Aharony, D.; Bialecki, R. A.; Abbott, B. M.; Barthlow, H. G.; Caccese, R.; Ghanekar, S.; Lengel, D.; Mccarthy, M.; Wenrich, B.; Undem, B.; Ohnmacht, C.; Shenvi, A.; Albert, J. S.; Brown, F.; Bernstein, P. R.; Russell, K. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J. Pharmacol. Exp. Ther. 2001 298 (1), 307-315.
16. 2 Antagonist. Bioorg. Med. Chem. Lett. 2000, 10, 1467-1470.
17. (e) Shih, N.-Y.; Albanese, M.; Aslanian, R.; Blythin, D.; Chen, X.; Duguma, L.; Gu, D.; Friary, R.; et al. Design and synthesis of the novel and orally active dual NK1 and NK2 antagonist Sch 205528. Abstr. Pap.-Am. Chem. Soc. 2000, MEDI-129.
18. (f) Bernstein, P. R.; Aharony, D.; Albert, J. S.; et al. Discovery of novel, orally active dual NK1/NK2 antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2769-2773.
19. 2 antagonist. Bioorg. Med. Chem. Lett. 2002, 12, 2125-2128.
20. (h) Nishi, T. Synthetic studies for the novel morpholine- and oxazolidine-based tachykinin receptor antagonists. Yuki Gosei Kagaku Kyokaishi 2002, 60 (7), 657-667.
21. (a) Ford-Hutchinson, A. W.; Rodger, I. W.; Jones, T. R. Drug News Perspect. Novel therapeutic strategies for the treatment of human bronchial asthma. 1992, 5 (9), 542-549.
22. (b) Geppetti, P.; Bertrand, C.; Ricciardolo, F. M. L.; Nadel, J. A. New aspects on the role ofkinins in neurogenic inflammation. Can. J. Physiol. Pharmacol. 1995, 7, 843-847.
23. (c) Advenier, C.; Lagente, V.; Boichot, E. The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation, and cough. Eur. Respir. J. 1997, 10, 1892-1906.
24. (d) Chapman, R. W.; Hey, J. A.; McLeod, R.; Minnicozzi, M.; Rizzo, Ch. Tachykinins in the lung. Drug News Perspect. 1998, 11 (8), 480-489.
25. (a) Murai, M.; Morimoto, H.; Maeda, Y.; Kiyotoh, S.; Nishikawa, M.; Fujii, T. Effects of FK-224, a novel compound NK-1 and NK-2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea-pigs. J. Pharmacol. Exp. Ther. 1992, 262, 403-408.
26. (b) Joos, G. F.; Van Schoor, J.; Kips, J. C.; Pauwels, R. A. The effect of inhaled FK-224, a tachykinin NK-1 and NK-2 receptor antagonist on neurokinin A-induced bronchoconstriction in asthmatics. Am. J. Respir. Crit. Care Med. 1996, 153, 1781-1784.
27. (c) Joos, G. F.; Pauwels, R. A. Tachykinin receptor antagonists: potential in airways diseases. Curr. Opin. Pharmacol. 2001, 1 (3), 235-241.
28. 2 Antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3, 5-bis(tri-fluoromethyl)benzamides and 3-[N′-3,5-bis(trifluoro-methyl)benzoyl-N-arylmethyl-N′- methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides. Bioorg. Med. Chem. Lett. 2001, 11, 3081-3084.
29. Lombardo, L.; Taylor, R. J. K. Silicon in organic synthesis; an improved preparation of α,β-unsaturated acids from carbonyl compounds. Synthesis 1978, 2, 131.
30. Rezler, E. M.; Fenton, R. R.; Esdale, W. J.; McKeage, M. J.; Russell, P. J.; Hambley, T. W. Preparation, characterisation, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum (II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)-and (S)-3-aminohexahydroazepinedichloroplatinum (II). J. Med. Chem. 1997, 40 (22), 3508-3515. L-α-Amino-ε-caprolactam is commercially available from Fluka Chemie AG, CH-9471 Buchs, Switzerland.
31. Preparation of rac-3: Gerspacher, M.; Hoshiko, K. Preparation of butenoic acids derivatives and their use in the treatment of rhinitis. Patent WO01/85696, 2001.
32. 2 neurokinin receptor antagonist (Abstract for Proceedings of the British Pharmacological Society, 2001). Brit. J. Pharmacol. 2002, 137 (4), 574.